Ecopipam 11.2 mg
Sponsors
Emalex Biosciences Inc., Emalex Biosciences Inc., Emalex Biosciences Inc.
Conditions
Tourette's DisorderTourette’s Disorder
Phase 3
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults with Tourette’s Disorder
CompletedCTIS2023-503494-38-00
Start: 2023-07-20End: 2025-01-16Target: 99Updated: 2024-11-08
A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder
RecruitingCTIS2023-503545-67-00
Start: 2024-04-30Target: 38Updated: 2026-01-27